Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Rupatadine safe, effective for chronic spontaneous urticaria, dermatitis, pruritus

12 Jul 2019

Rupatadine for the management of patients with chronic spontaneous urticaria, dermatitis and pruritus is safe in the short and long term, according to a recent Japan study.

Researchers conducted a multicentre, open-label clinical trial including 206 participants who were given the study medication. Efficacy was assessed primarily through the change in total pruritus score (TPS) from baseline to week 2. Rupatadine was administered initially at 10 mg once daily, though updosing to 20 mg was allowed starting week 3.

Of the participants, majority had eczema or dermatitis (n=132); 58 had pruritus and 16 had chronic spontaneous urticaria.

The primary efficacy analysis revealed a significant 2-week change in TPS (–1.241, 95 percent CI, –1.450 to –1.033; p<0.001). This remained significant even when restricting analysis to adolescents (mean change, –0.745; p=0.008) or adults (mean change, –1.304; p<0.001).

Disaggregating according to disease type likewise did not meaningfully change the results. Mean changes in disease score for those with eczema or dermatitis, pruritus and chronic spontaneous urticaria were –1.071, –1.183 and –2.971, respectively, and all of which were significant (p<0.001).

In terms of safety, the incidence rate of adverse events from baseline to week 2 was 18.9 percent. This climbed to 38.6 percent between weeks 3 and 12, and further to 67.8 percent between weeks 13 and 52. Adverse drug reactions showed an opposite, downward trend, starting at 9.7 percent between weeks 1 and 2 and dropping to 1.7 percent between weeks 13 and 52.

 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).